65-asset-1-16127989617232.png
  • HOME
  • BACKGROUND
  • THE TEAM
  • PIPELINE
  • CONTACT
BUZZARD PHARMACEUTICAL
  • HOME
  • BACKGROUND
  • THE TEAM
  • PIPELINE
  • CONTACT

DEVELOPING ISUNAKINRA

 a potent IL-1 inhibitor - in cancer indications

Buzzard Pharmaceuticals AB

 

• is based in Stockholm and was founded in 2016 by Urban Paulsson and Maarten de Château

 

• has a focus on developing drugs in oncology

 

• has acquired the rights to isunakinra from Eleven Biotherapeutics in 2017 with the intent to re-position isunakinra in cancer indications

 

• isunakinra is a chimeric protein binding to IL1R1 and inhibiting IL-1 signaling with high potency

 

• the molecule was previously developed for eye diseases (in a topical formulation) 

 

• a phase I/II trial in solid tumor patients was initiated in 2020 at the Baylor Research Institute, Dallas, TX (NCT04121442)

THE TEAM

066166012650-buzzardpharmaceuticalsp-002.jpg
Maarten de Château, MD PhD
• CEO
• Co-founder of Cormorant Pharmaceuticals, sold to BMS in 2016. 
The sole asset was HuMax-IL8 an antibody targeting IL-8
• Previously at Sobi, Sanofi-Aventis, Swedbank Markets, Aragon Securities, Uppsala University, Harvard Medical School
2653-urbanfärg500px-15689750282458.jpg
Urban Paulsson, Lawyer
• Chairman
• Co-founder of Cormorant Pharmaceuticals, sold to BMS in 2016
• Previously at law firms Norida, Karlerö and Bird&Bird and at Vitrolife and Pharmacia
2506216062652-hans-olivecrona1.jpg
Hans Olivecrona, MD PhD
• CMO
• Previously at Sobi, Immedica Pharma, Karolinska University Hospital and the Karolinska Institute

Contact US

SEND

Visiting Adress: Skeppsbron 16, 111 30 Stockholm, Sweden

1-asset-1-16127989617232.png
COPYRIGHT © BUZZARD PHARMACEUTICALS. ALL RIGHTS RESERVED.